The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Prognosis of Gastric Cancer
NCT04819958 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2021-04-15
Summary
The purpose of this study is to explore the effect of immunological heterogeneity of tumor microenvironment in the short-term outcome and long-term outcome of patients with gastric cancer.
Conditions
- Stomach Cancer
Sponsors & Collaborators
-
Fujian Medical University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-31
- Primary Completion
- 2021-08-30
- Completion
- 2021-08-30
Countries
- China
Study Locations
More Related Trials
-
Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
NCT06915389 ·Status: RECRUITING
-
Genomic Evolution of Metastasis in Gastric Cancer
NCT05061082 ·Status: UNKNOWN
-
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
NCT04842916 ·Status: RECRUITING
-
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
NCT06109805 ·Status: COMPLETED
-
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
NCT04086888 ·Status: UNKNOWN
-
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
NCT06202781 ·Status: RECRUITING
-
Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
NCT06277453 ·Status: ACTIVE_NOT_RECRUITING
-
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
NCT06134011 ·Status: ACTIVE_NOT_RECRUITING
-
The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
NCT07069842 ·Status: RECRUITING
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING
-
Transcriptomic Signatures in Gastric Adenocarcinoma
NCT05319392 ·Status: UNKNOWN
-
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
NCT02583659 ·Status: UNKNOWN
-
the Optimal Surveillance Frequency for Stage II/III Gastric Cancer
NCT05465993 ·Status: COMPLETED
-
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
NCT06452329 ·Status: COMPLETED
-
Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer
NCT05348161 ·Status: UNKNOWN ·Phase: NA
-
Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma
NCT05270824 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer
NCT02179463 ·Status: UNKNOWN
-
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
NCT05610332 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
NCT06376773 ·Status: COMPLETED
-
Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study
NCT01558011 ·Status: TERMINATED ·Phase: PHASE2
-
The Efficacy of Precision Treatment for Gastric Cancer Guided by Molecular Profiling
NCT04501887 ·Status: UNKNOWN
-
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
NCT06235164 ·Status: ACTIVE_NOT_RECRUITING
-
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
NCT05464875 ·Status: RECRUITING
-
Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor
NCT03399253 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
NCT04006821 ·Status: UNKNOWN ·Phase: PHASE2